Form 4: Sana Biotechnology Director Receives Stock Option Grant

Director Robert L. Rosiello was granted 90,000 stock options in Sana Biotechnology, Inc. as part of a standard equity incentive.

Summary

• Director Robert L. Rosiello received a grant of 90,000 stock options on June 4, 2026.
• The options have an exercise price of $2.96 per share.
• The options are set to vest in full on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• The value of the options is subject to market volatility and the future performance of Sana Biotechnology's common stock.

Future Outlook

The options vest in one year, indicating a retention and alignment strategy for the director through the 2027 annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term clinical and commercial development.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotechnology firms.
• The use of a one-year cliff vesting period is a common governance practice to ensure director commitment.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon potential future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Sana Biotechnology, SANA, Director Compensation, Stock Options, SEC Form 4, Insider Transaction